Table 1 Demographics and baseline characteristics of participants in the analysis set

From: [11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial

 

All participantsa (n = 128)

Surgery (n = 78)

Medical (n = 50)

P value for differences between treatment groups

Sex

   

0.703

Male

87 (68.0%)

54 (69.2%)

33 (66.0%)

 

Female

41 (32.0%)

24 (30.8%)

17 (34.0%)

 

Median age (years)

52 (42.5–60.0)

52 (43–60)

52.5 (41–61)

0.874

Median BMI (kg m−2)

29.7 (26.7–34.0)

30.5 (26.3–34.8)

29.1 (26.9–33.2)

0.336

Ethnicity

   

0.007

White

75 (58.6%)

53 (67.9%)

22 (44%)

 

Blackb

38 (29.7%)

15 (19.2%)

23 (46%)

 

Asian

14 (10.9%)

9 (11.5%)

5 (10%)

 

Other

1 (0.8%)

1 (1.3%)

0 (0%)

 

Clinic BP at screening

    

SBP median (mmHg)

148 (138–166)

149 (138–166)

145 (138–166)

0.705

DBP median (mmHg)

91 (82–103)

91 (81–102)

89 (84–104)

0.667

Median NDC

2 (2–3)

2 (2–3)

2 (2–3)

0.929

Median DDD

3.5 (2.1–6.0)

4.0 (2.3–6.5)

3.1 (2.0–6.0)

0.199

  1. aThe demographics and baseline characteristics of patients in the analysis set (that is, those who had completed their allocated treatment and follow-up (6 months post-adrenalectomy or after 9–12 months of medical therapy) at the time the study were censored). Data for patients managed with surgery or medical therapy are also shown.
  2. bBlack patients comprised 40% of 108 patients recruited in London hospitals, where 14% of the local population is Black.
  3. Numbers in brackets indicate percentages, whereas ranges in brackets indicate first and third quartiles. For categorical data, the Fisher’s exact test was used. For continuous data, the Mann–Whitney–Wilcoxon test was used.
  4. BMI, body mass index; BP, blood pressure; DDD, defined daily dose of antihypertensive medication; DBP, diastolic blood pressure; NDC, number of different classes of antihypertensive medication.
Back to article page